From Financial Modeling Prep: 2025-05-14 11:52:00

Citi downgraded AbbVie from Buy to Neutral, lowering price target to $205 from $210. Shares fell over 2% intra-day. Despite strong near-term performance, concerns about long-term outlook and pipeline growth drove the decision. Key worries include thin late-stage pipeline and exposure to potential U.S. policy changes. Flagship drugs face no loss of exclusivity until after 2030, but structural risks weaken defensive positioning. The downgrade reflects a more cautious stance on AbbVie’s ability to maintain premium valuation without pipeline expansion or policy clarity.



Read more at Financial Modeling Prep:: Citi Downgrades AbbVie to Neutral, Shares Down 2%